Anterior Segment Company Showcase - LacriScience at OIS@AAO 2016.
Presenter:
Chris Geddes, PhD, Chief Biomedical/Plasmonics Consultant
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
The document summarizes the LacriPen, a handheld portable ophthalmic diagnostic instrument developed by LacriScience that can measure tear osmolarity and other biomarkers using surface plasmon resonance. It has advanced optics and sensors on the tip that allow for measurement of tear osmolarity, MMP-9, viruses, and other analytes with high precision and accuracy. The device has intellectual property protection and LacriScience's business plan involves commercializing the LacriPen for use in diagnosing dry eye disease and other applications in ophthalmology and general medicine.
This document summarizes Bausch + Lomb's approach to driving innovation through internal development, acquiring companies, and licensing technologies. It highlights Bausch + Lomb's extensive product pipeline that addresses industry trends toward multiple-function technologies, compliance-supporting innovations, and presbyopia correction solutions. The document emphasizes Bausch + Lomb's flexible and nimble approach to research and development focused on project merits rather than origin.
The LacriPen is a handheld portable device that can measure osmolality and biomarkers from tears in 1 second using surface plasmon resonance. It has achieved a goal of ±2 mOsms/L for osmolality measurements and can detect MMP-9 concentrations from 1-200 ng/ml with precision of ±5 ng/ml. Clinical testing of the LacriPen's ability to measure osmolality and detect smart diagnostics has been approved and initial testing has been completed. The portable design allows for point-of-care diagnostics without the need for anesthesia or eyelid scraping.
The document discusses Presbia Flexivue Microlens, an investigational intracorneal inlay to treat presbyopia. It notes that there are 1.8 billion presbyopes worldwide and ophthalmologists are motivated to treat this large market. The technology involves implanting a small hydrophilic acrylic lens in the cornea using existing femtosecond lasers. The author's clinical experience found the procedure had a short learning curve, excellent uncorrected near vision, and distance vision was unaffected. The inlay shows potential for treating presbyopia, improving vision after cataracts or LASIK.
The document discusses Cassini, a corneal imaging system that provides comprehensive analysis of the anterior and posterior cornea to reduce refractive surprises. It has 6 key features: 1) total corneal analysis, 2) ocular surface diagnostics, 3) iris registration, 4) integrated surgical workflow, 5) data mining, and 6) proactive solutions. Cassini provides valuable pre-op information and seamlessly integrates with other technologies. It uses multi-colored LEDs and 2nd Purkinje imaging to map total corneal astigmatism. Cassini has been used in over 300,000 cataract patients to date. It can drive premium procedures and adoption of premium IOLs while also streamlining surgical workflows.
The document discusses an artificial intraocular lens (AIOL) called the FluidVision that mimics the eye's natural accommodative process. It is the first true shape changing, fluid-driven IOL. Early results from a 23 patient pilot study show promising results with a straightforward surgical technique. Bench testing shows the FluidVision provides excellent image quality over a range of powers as it continuously varies between far and near focal points by inflating and deflating the lens using fluid movements. PowerVision is developing additional innovations like a toric version and post-implant adjustment capabilities.
This document summarizes information about the VisAbility Micro-Insert System, an investigational device for treating presbyopia. It provides details on the clinical trial results showing the device improved near vision without compromising distance vision. Over multiple time periods, a high percentage of patients achieved good near vision both with and without glasses. The device also showed stability in refractive error and high patient satisfaction rates. The summary concludes with benefits of the VisAbility procedure compared to other presbyopia surgeries, such as preserving full range of focus and stereopsis while having a superior safety profile.
The document summarizes the LacriPen, a handheld portable ophthalmic diagnostic instrument developed by LacriScience that can measure tear osmolarity and other biomarkers using surface plasmon resonance. It has advanced optics and sensors on the tip that allow for measurement of tear osmolarity, MMP-9, viruses, and other analytes with high precision and accuracy. The device has intellectual property protection and LacriScience's business plan involves commercializing the LacriPen for use in diagnosing dry eye disease and other applications in ophthalmology and general medicine.
This document summarizes Bausch + Lomb's approach to driving innovation through internal development, acquiring companies, and licensing technologies. It highlights Bausch + Lomb's extensive product pipeline that addresses industry trends toward multiple-function technologies, compliance-supporting innovations, and presbyopia correction solutions. The document emphasizes Bausch + Lomb's flexible and nimble approach to research and development focused on project merits rather than origin.
The LacriPen is a handheld portable device that can measure osmolality and biomarkers from tears in 1 second using surface plasmon resonance. It has achieved a goal of ±2 mOsms/L for osmolality measurements and can detect MMP-9 concentrations from 1-200 ng/ml with precision of ±5 ng/ml. Clinical testing of the LacriPen's ability to measure osmolality and detect smart diagnostics has been approved and initial testing has been completed. The portable design allows for point-of-care diagnostics without the need for anesthesia or eyelid scraping.
The document discusses Presbia Flexivue Microlens, an investigational intracorneal inlay to treat presbyopia. It notes that there are 1.8 billion presbyopes worldwide and ophthalmologists are motivated to treat this large market. The technology involves implanting a small hydrophilic acrylic lens in the cornea using existing femtosecond lasers. The author's clinical experience found the procedure had a short learning curve, excellent uncorrected near vision, and distance vision was unaffected. The inlay shows potential for treating presbyopia, improving vision after cataracts or LASIK.
The document discusses Cassini, a corneal imaging system that provides comprehensive analysis of the anterior and posterior cornea to reduce refractive surprises. It has 6 key features: 1) total corneal analysis, 2) ocular surface diagnostics, 3) iris registration, 4) integrated surgical workflow, 5) data mining, and 6) proactive solutions. Cassini provides valuable pre-op information and seamlessly integrates with other technologies. It uses multi-colored LEDs and 2nd Purkinje imaging to map total corneal astigmatism. Cassini has been used in over 300,000 cataract patients to date. It can drive premium procedures and adoption of premium IOLs while also streamlining surgical workflows.
The document discusses an artificial intraocular lens (AIOL) called the FluidVision that mimics the eye's natural accommodative process. It is the first true shape changing, fluid-driven IOL. Early results from a 23 patient pilot study show promising results with a straightforward surgical technique. Bench testing shows the FluidVision provides excellent image quality over a range of powers as it continuously varies between far and near focal points by inflating and deflating the lens using fluid movements. PowerVision is developing additional innovations like a toric version and post-implant adjustment capabilities.
This document summarizes information about the VisAbility Micro-Insert System, an investigational device for treating presbyopia. It provides details on the clinical trial results showing the device improved near vision without compromising distance vision. Over multiple time periods, a high percentage of patients achieved good near vision both with and without glasses. The device also showed stability in refractive error and high patient satisfaction rates. The summary concludes with benefits of the VisAbility procedure compared to other presbyopia surgeries, such as preserving full range of focus and stereopsis while having a superior safety profile.
SightGlass Vision has developed lenses that can safely and effectively reduce myopia progression in children. Myopia is a growing global problem, with hundreds of millions expected to suffer vision impairment due to complications if left untreated. Current solutions are only marginally effective and carry safety risks. SightGlass lenses work by providing peripheral blur and reducing peripheral hyperopia based on clinical trials, demonstrating over a 90% reduction in axial eye growth. The company is seeking funding to conduct a pivotal study and launch the lenses globally to address this major public health issue.
The document summarizes an ophthalmology innovation summit presentation about the Raindrop Near Vision Inlay. The Raindrop is a small hydrogel inlay implanted between the cornea and Bowman's layer to improve near and intermediate vision for presbyopia. Clinical trial results on 340 patients found 95% achieved 20/25 or better near vision, low rates of visual side effects, and high patient satisfaction at 12 months. Additional results on pseudophakic patients at 6 months also showed high rates of good near, intermediate, and distance-corrected vision. The Raindrop aims to provide an alternative to reading glasses or bifocals through a quick, minimally invasive procedure with high light transmission and compatibility with intraocular lenses.
Emmetrope Inc. is developing a line of accommodating intraocular lenses (IOLs) called ActaLens, ActaLens-Duo, and ActaLens-SC. The ActaLens models use a restrained hinge mechanism to allow movement of the optic when the eye focuses. Early clinical studies show the ActaLens providing over 0.5mm of movement and an estimated 0.5 diopters of accommodation. The dual optic ActaLens-Duo and shape changing ActaLens-SC are expected to provide even greater accommodation.
SPOTLIGHT ON THE PREMIUM CHANNEL – AcuFocusHealthegy
Presentation from OIS@ASCRS 2016
Nick Tarantino, OD, Chief Global Clinical & Regulatory Affairs Officer
Video Presentation:
https://www.youtube.com/watch?v=Nc4T9u62rBQ&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=34
SPOTLIGHT ON THE PREMIUM CHANNEL - Abbott Medical OpticsHealthegy
Presentation from OIS@ASCRS 2016
Leonard Borrmann, Divisional VP, R&D
Video Presentation:
https://www.youtube.com/watch?v=02VOUB17Xp8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=38
ZeptoTM is a device that uses the Purkinje image to anchor cataract surgery on the visual axis. It completed a US clinical trial in 80 days and was submitted to the FDA for 510(k) clearance in March 2017. The device has launched in India, Germany, and is planned for the US summer 2017. Development is also underway for an automated ZeptoTM for posterior capsulotomy. ZeptoTM aims to increase practice efficiency, allow for difficult cases to be performed easily and safely, and has the potential to redefine cataract surgery.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
Presentation from OIS@ASCRS 2016
Joseph Boorady, President & CEO
Video Presentaion:
https://www.youtube.com/watch?v=I_rVlB71VX4&index=32&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
Richard L. Lindstrom, MD's "Thoughts on Corneal and Lens based Refractive Surgery to Enhance Near Vision in the USA: 2015" presentation from OIS@ASCRS 2015
Presentation from OIS@ASCRS 2016
Dave Van Meter, President & CEO
Video Presentations:
https://www.youtube.com/watch?v=aisY-FTnTyM&index=26&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
The retina is the light-sensitive layer at the back of the eye. A retinal tear or hole allows fluid from behind the eye to enter and cause a retinal detachment. Risk factors for retinal detachment include increasing age, family history, prior eye surgery or trauma, high nearsightedness, and eye conditions like diabetes. Symptoms include new floaters, flashes of light, blurred or blocked vision. Treatment options depend on whether there is a tear, hole, or full detachment, but may involve laser treatment, cryotherapy, or vitrectomy surgery to repair, seal, and reattach the retina. Regular eye exams are important for those at higher risk.
Presentation from OIS@ASCRS 2016
John Hendrick, President & CEO
Video Presentation:
https://www.youtube.com/watch?v=c2J1g7HYuek&index=24&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
DIAGNOSTICS-IMPACT ON THE PREMIUM CHANNEL - AlconHealthegy
Presentation from OIS@ASCRS 2016
Seba Leoni, VP & Global Head, Surgical Suite
Video Presentation:
https://www.youtube.com/watch?v=hidfQJsrV4o&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=24
Anterior Segment Company Showcase - Z lensHealthegy
Anterior Segment Company Showcase - Z lens at OIS@AAO 2016.
Presenter:
Paul Beer, MD, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Dr. Julian Theng launched the first edition of "A Long-Sighted Look at Presbyopia – Facts, Fiction and Hope" in 2007 to address problems with presbyopia. Eagle Eye Centre is committed to leading treatment for presbyopia and providing patients with the best possible care through a thorough understanding of their situations and a comprehensive range of treatment options. Presbyopia is caused by changes in the lens and supporting muscles that make the lens stiffer and less elastic with age. Treatments for presbyopia include LASIK monovision, corneal inlays, progressive spectacles, multifocal contact lenses, and multifocal lens implants.
The document summarizes research on the IC-8TM small-aperture intraocular lens. Optical modeling shows it extends the depth of focus compared to monofocal and bifocal lenses. Clinical data from patients found it provided a broad range of clear vision from near to far, with minimal visual symptoms. The IC-8TM lens can be implanted using standard cataract surgery techniques and allows for posterior segment assessments and procedures.
Endo Optiks has introduced a new triple-function 23 gauge laser endoscope that provides laser, light, and imaging capabilities through a single 23 gauge cannula. The endoscope fits through standard 23 gauge trocar systems and will allow direct visualization and treatment of the posterior segment through a small incision. Several retina specialists commented that the 23 gauge endoscope will increase the number of cases that can be treated endoscopically and simplify many vitrectomy tasks.
Presentation from OIS@ASCRS 2016
Michael Onuscheck, Global Franchise Head, Alcon Surgical
Video Presentation:
https://www.youtube.com/watch?v=RxwelffneOc&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=35
The document discusses the IntraLase Method for LASIK eye surgery. It describes the IntraLase Method as a 100% blade-free approach that uses laser pulses to create a corneal flap instead of a microkeratome blade. This eliminates the risk of complications associated with the blade and clinical studies show it provides better visual results with more patients achieving 20/20 vision or better. The document promotes the IntraLase Method as the safest, most advanced treatment available for LASIK.
Anterior Segment Company Showcase - TearScienceHealthegy
Anterior Segment Company Showcase - TearScience at OIS@AAO 2016.
Presenter:
Joseph Boorady, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
This document describes a patented, cloud-based system called MD Backline that automates patient contact before and after office visits through email or SMS. The system aims to improve patient care by asking how treatment is going, providing customized education, answering questions, collecting outcomes data, and generating research revenue. MD Backline has been tested with over 5,000 responses showing high response rates and positive feedback. It has delivered value to practices by reducing calls and documenting education. After two years of funding operations through $900k in revenue, projections estimate $4.9M in year 1 revenue growing to over $70M in year 3. The next steps are to expand to more specialties, EHR platforms, and seek investment partners.
SightGlass Vision has developed lenses that can safely and effectively reduce myopia progression in children. Myopia is a growing global problem, with hundreds of millions expected to suffer vision impairment due to complications if left untreated. Current solutions are only marginally effective and carry safety risks. SightGlass lenses work by providing peripheral blur and reducing peripheral hyperopia based on clinical trials, demonstrating over a 90% reduction in axial eye growth. The company is seeking funding to conduct a pivotal study and launch the lenses globally to address this major public health issue.
The document summarizes an ophthalmology innovation summit presentation about the Raindrop Near Vision Inlay. The Raindrop is a small hydrogel inlay implanted between the cornea and Bowman's layer to improve near and intermediate vision for presbyopia. Clinical trial results on 340 patients found 95% achieved 20/25 or better near vision, low rates of visual side effects, and high patient satisfaction at 12 months. Additional results on pseudophakic patients at 6 months also showed high rates of good near, intermediate, and distance-corrected vision. The Raindrop aims to provide an alternative to reading glasses or bifocals through a quick, minimally invasive procedure with high light transmission and compatibility with intraocular lenses.
Emmetrope Inc. is developing a line of accommodating intraocular lenses (IOLs) called ActaLens, ActaLens-Duo, and ActaLens-SC. The ActaLens models use a restrained hinge mechanism to allow movement of the optic when the eye focuses. Early clinical studies show the ActaLens providing over 0.5mm of movement and an estimated 0.5 diopters of accommodation. The dual optic ActaLens-Duo and shape changing ActaLens-SC are expected to provide even greater accommodation.
SPOTLIGHT ON THE PREMIUM CHANNEL – AcuFocusHealthegy
Presentation from OIS@ASCRS 2016
Nick Tarantino, OD, Chief Global Clinical & Regulatory Affairs Officer
Video Presentation:
https://www.youtube.com/watch?v=Nc4T9u62rBQ&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=34
SPOTLIGHT ON THE PREMIUM CHANNEL - Abbott Medical OpticsHealthegy
Presentation from OIS@ASCRS 2016
Leonard Borrmann, Divisional VP, R&D
Video Presentation:
https://www.youtube.com/watch?v=02VOUB17Xp8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=38
ZeptoTM is a device that uses the Purkinje image to anchor cataract surgery on the visual axis. It completed a US clinical trial in 80 days and was submitted to the FDA for 510(k) clearance in March 2017. The device has launched in India, Germany, and is planned for the US summer 2017. Development is also underway for an automated ZeptoTM for posterior capsulotomy. ZeptoTM aims to increase practice efficiency, allow for difficult cases to be performed easily and safely, and has the potential to redefine cataract surgery.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
Presentation from OIS@ASCRS 2016
Joseph Boorady, President & CEO
Video Presentaion:
https://www.youtube.com/watch?v=I_rVlB71VX4&index=32&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
Richard L. Lindstrom, MD's "Thoughts on Corneal and Lens based Refractive Surgery to Enhance Near Vision in the USA: 2015" presentation from OIS@ASCRS 2015
Presentation from OIS@ASCRS 2016
Dave Van Meter, President & CEO
Video Presentations:
https://www.youtube.com/watch?v=aisY-FTnTyM&index=26&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
The retina is the light-sensitive layer at the back of the eye. A retinal tear or hole allows fluid from behind the eye to enter and cause a retinal detachment. Risk factors for retinal detachment include increasing age, family history, prior eye surgery or trauma, high nearsightedness, and eye conditions like diabetes. Symptoms include new floaters, flashes of light, blurred or blocked vision. Treatment options depend on whether there is a tear, hole, or full detachment, but may involve laser treatment, cryotherapy, or vitrectomy surgery to repair, seal, and reattach the retina. Regular eye exams are important for those at higher risk.
Presentation from OIS@ASCRS 2016
John Hendrick, President & CEO
Video Presentation:
https://www.youtube.com/watch?v=c2J1g7HYuek&index=24&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
DIAGNOSTICS-IMPACT ON THE PREMIUM CHANNEL - AlconHealthegy
Presentation from OIS@ASCRS 2016
Seba Leoni, VP & Global Head, Surgical Suite
Video Presentation:
https://www.youtube.com/watch?v=hidfQJsrV4o&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=24
Anterior Segment Company Showcase - Z lensHealthegy
Anterior Segment Company Showcase - Z lens at OIS@AAO 2016.
Presenter:
Paul Beer, MD, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Dr. Julian Theng launched the first edition of "A Long-Sighted Look at Presbyopia – Facts, Fiction and Hope" in 2007 to address problems with presbyopia. Eagle Eye Centre is committed to leading treatment for presbyopia and providing patients with the best possible care through a thorough understanding of their situations and a comprehensive range of treatment options. Presbyopia is caused by changes in the lens and supporting muscles that make the lens stiffer and less elastic with age. Treatments for presbyopia include LASIK monovision, corneal inlays, progressive spectacles, multifocal contact lenses, and multifocal lens implants.
The document summarizes research on the IC-8TM small-aperture intraocular lens. Optical modeling shows it extends the depth of focus compared to monofocal and bifocal lenses. Clinical data from patients found it provided a broad range of clear vision from near to far, with minimal visual symptoms. The IC-8TM lens can be implanted using standard cataract surgery techniques and allows for posterior segment assessments and procedures.
Endo Optiks has introduced a new triple-function 23 gauge laser endoscope that provides laser, light, and imaging capabilities through a single 23 gauge cannula. The endoscope fits through standard 23 gauge trocar systems and will allow direct visualization and treatment of the posterior segment through a small incision. Several retina specialists commented that the 23 gauge endoscope will increase the number of cases that can be treated endoscopically and simplify many vitrectomy tasks.
Presentation from OIS@ASCRS 2016
Michael Onuscheck, Global Franchise Head, Alcon Surgical
Video Presentation:
https://www.youtube.com/watch?v=RxwelffneOc&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=35
The document discusses the IntraLase Method for LASIK eye surgery. It describes the IntraLase Method as a 100% blade-free approach that uses laser pulses to create a corneal flap instead of a microkeratome blade. This eliminates the risk of complications associated with the blade and clinical studies show it provides better visual results with more patients achieving 20/20 vision or better. The document promotes the IntraLase Method as the safest, most advanced treatment available for LASIK.
Anterior Segment Company Showcase - TearScienceHealthegy
Anterior Segment Company Showcase - TearScience at OIS@AAO 2016.
Presenter:
Joseph Boorady, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
This document describes a patented, cloud-based system called MD Backline that automates patient contact before and after office visits through email or SMS. The system aims to improve patient care by asking how treatment is going, providing customized education, answering questions, collecting outcomes data, and generating research revenue. MD Backline has been tested with over 5,000 responses showing high response rates and positive feedback. It has delivered value to practices by reducing calls and documenting education. After two years of funding operations through $900k in revenue, projections estimate $4.9M in year 1 revenue growing to over $70M in year 3. The next steps are to expand to more specialties, EHR platforms, and seek investment partners.
Anterior Segment Company Showcase - Mati TherapeuticsHealthegy
Anterior Segment Company Showcase - Mati Therapeutics at OIS@AAO 2016.
Presenter:
Bob Butchofsky, Founder & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
The document summarizes the development of an anti-VEGF eye drop called PAN-90806 being developed by PanOptica for the treatment of wet age-related macular degeneration and other retinal diseases. It describes positive preliminary results from a Phase 1/2 clinical trial in wet AMD patients showing biological activity with no systemic side effects. It also outlines plans to further study PAN-90806 using an advanced formulation in additional clinical trials for wet AMD and proliferative diabetic retinopathy. Developing an effective anti-VEGF eye drop could provide significant benefits over frequent eye injections.
1) Alcon and Google have partnered to develop "smart lens" technology to address unmet medical needs in eye care, such as treating cataracts, age-related macular degeneration, glaucoma, and presbyopia.
2) The collaboration aims to create glucose-sensing contact lenses to help diabetics manage their condition, and accommodating contact lenses or IOLs to restore near vision for presbyopes.
3) While smart lenses offer advantages like ease of use and data sharing, challenges include ensuring patient privacy as health data is collected and regulatory hurdles in approving new mobile medical devices.
Vision Medicines is developing two drug candidates, VM100 and VM200, to treat retinal diseases with high unmet medical need and large market opportunities. VM100 is in Phase 2/3 development for geographic atrophy and intermediate AMD, with a combined $20B market. VM200 is in preclinical development for Stargardt disease, an orphan indication with no approved therapies and a $6B market opportunity. Both drugs address the underlying disease mechanisms and have demonstrated preclinical efficacy in preserving retinal structure and function. Vision Medicines aims to develop these assets and consolidate the fragmented ophthalmology space, which has fewer products per company than other therapeutic areas.
The document summarizes the FluidVision accommodating intraocular lens (IOL) from PowerVision. It describes how the lens works by mimicking the eye's natural accommodative process through fluid movement. Clinical studies show the lens provides both subjective and objective accommodation with excellent visual outcomes. A new FluidVision 20/20 lens is introduced that aims to achieve 20/20 vision at all distances through smaller incisions.
Mati Therapeutics has designed and tested over 70 iterations of its L-shaped punctal plug drug delivery device (L-PPDS). The L-PPDS provides one-directional drug release into the tear film from a solid drug-eluting core wrapped in a non-permeable membrane. Testing shows retention rates of over 90% for the L-PPDS. Mati has formulated the L-PPDS to elute drugs for glaucoma, allergy, anti-inflammatory conditions, and dry eye over 2 weeks with a tunable initial burst. The company's intellectual property portfolio includes over 60 issued patents covering the device design and manufacturing through 2034.
This document provides an overview of private funding trends in healthcare from Jon Norris, Managing Director at Silicon Valley Bank. Some key points:
1) Venture investment in healthcare has grown significantly since 2000, with biopharma receiving around 15% of total venture dollars and medical devices receiving around 5% in recent years.
2) Crossover investors have become increasingly active in healthcare venture deals in recent years, contributing to larger financing rounds and higher valuations.
3) Exits through M&A and IPOs have increased substantially since 2005, with 2015 on pace to match or exceed record levels from previous years.
4) Biopharma and medical device valuations and dollars raised in private financings
This document provides a summary of key events and developments in ophthalmology in 2015. It discusses growth in attendance at major ophthalmology conferences, FDA drug and device approvals, positive results from phase 3 trials of gene therapy for RPE65-mediated retinal dystrophy and Humira for uveitis. It also reviews trends in the use of anti-VEGF drugs to treat wet AMD, global rates of IVT injections, the ophthalmic drug market, and causes of blindness worldwide. Tables and graphs are included to illustrate drugs, procedures, technologies, and market data.
1. RPS Diagnostics develops novel point-of-care technology platforms, reagents, and therapeutic agents for eye care and infectious disease testing.
2. Their proprietary platforms include InflammaDry for dry eye detection and FebriDx for respiratory fever testing. They have 3 additional POC tests in clinical trials and a robust pipeline of products.
3. Their products help physicians provide better patient management by reducing misdiagnosis, unnecessary treatment, and disease spread through rapid, easy-to-use testing. This improves patient outcomes and lowers costs.
Eye diseases remain a significant global problem, with glaucoma affecting an estimated 80 million people by 2020. Dry eye also has a high prevalence, affecting an estimated 15-18% of the general population or 30 million patients in the US. The eye care market is poised for growth driven by an aging population, expanded access to healthcare, and advances in drug delivery and devices. However, generics and cost controls pose barriers to growth. The pharmaceutical innovation ecosystem has expanded and diversified beyond large pharmaceutical companies, with biotech startups and regional players contributing more new drug approvals in recent years.
Aerie Pharmaceuticals is developing Rhopressa and Roclatan as once-daily eye drops to lower intraocular pressure for glaucoma. Rhopressa demonstrated efficacy in Phase 3 trials and Aerie expects to file an NDA in Q3 2016. Roclatan achieved all endpoints in a Phase 2b trial and is now in Phase 3 trials. Preclinical research also shows Rhopressa may modify diseased tissue and increase blood flow in the eye. Aerie is exploring AR-13154 for wet AMD which showed lesion size reduction exceeding the leading product in studies. The company collaborates with other organizations on delivery technologies and product candidates for the front and back of the eye.
The document discusses a small aperture intraocular lens (IOL) called the IC-8 IOL. It summarizes results from a post-market study showing the IC-8 IOL provides excellent visual acuity at far, intermediate, and near distances. Specifically, it found mean binocular uncorrected visual acuities of 20/20 or better for far and intermediate distances and 20/32 for near distances. The IC-8 IOL also demonstrated increased tolerance to uncorrected astigmatism compared to monofocal IOLs and maintained contrast sensitivity similar to monofocal IOLs. Additionally, the IC-8 IOL requires no special surgical technique for implantation and allows for ocular imaging and retinal procedures
Anterior Segment Company Showcase - Mynosys Cellular DevicesHealthegy
This document discusses the ZeptoTM Capsulotomy System, a new device for performing capsulotomies during cataract surgery. The system uses femtosecond laser technology to perform automated, precise capsulotomies. Clinical experience with the device in 34 patients showed it created tag-free, complete capsulotomies with no complications. Upcoming clinical studies in the US and EU are planned to obtain regulatory approval, with market introduction expected in select countries starting in January 2017. The ZeptoTM system is presented as satisfying unmet needs by maintaining surgical efficiency while allowing capsulotomies for difficult cases like small pupils or weak zonules.
Anterior Segment Company Showcase - ReVision OpticsHealthegy
This document discusses the Raindrop Near Vision Inlay made by ReVision Optics:
- It is a small hydrogel inlay placed under the corneal flap to gently reshape the cornea and create a near focal point for reading while maintaining distance vision.
- Clinical trial results showed significant and sustained improvements in near vision, with no loss of distance vision over 2 years.
- Market research found high interest from both patients and eye care professionals in the Raindrop procedure. ReVision's website and social media posts about Raindrop's benefits drove thousands of views and requests from potential surgeons in a short time period.
- The priority is to continue demonstrating positive patient outcomes to support increasing adoption of the Raindrop
Spark Therapeutics is developing gene therapies for genetic disorders including SPK-RPE65 for retinal diseases. SPK-RPE65 achieved highly statistically significant results in a pivotal Phase 3 trial, demonstrating long-lasting benefits on vision tests over 3 years. If approved, it could be the first gene therapy approved in the US for a genetic disease. Spark is applying its validated AAV gene therapy platform to expand its pipeline to additional retinal diseases and indications.
Anterior Segment Company Showcase - SightLifeHealthegy
Anterior Segment Company Showcase - SightLife at OIS@AAO 2016.
Presenter:
Monty Montoya, CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
This document discusses dry eye, including its causes, diagnostic tests, and treatment options. It provides an overview of dry eye as one of the most common conditions seen by eye practitioners. Key points include:
- Dry eye is caused by dysfunction of the lacrimal functional unit, which includes the tear glands, tear film, and ocular surface.
- Common diagnostic tests include tear break-up time, Schirmer test, and staining of the ocular surface with dyes. Newer tests measure tear osmolarity.
- Treatment focuses on managing symptoms, treating underlying causes, and stabilizing the tear film through lubricating eye drops, ointments, or gels. Preservative
Dry eye is a disease of ocular surface. It occurs when eye do not produce enough tears. Normally the eye bathes itself in tears by producing tears in a slow and steady rate which helps the eye to remain constantly moist and lubricated which maintain visions and comfort. Tears are a combination of water, for moisture; oils, for lubrication; mucus, for even spreading and antibodies, an special protein, for resistance to infection. Any imbalance in this system can lead to dry eye.
The document discusses various uses of lasers in ophthalmology, including both diagnostic and therapeutic applications. It focuses on therapeutic laser treatments, which can be used to treat retinal detachments, glaucoma, and cataracts. A major application is refractive corneal surgery using lasers to correct refractive errors like myopia, hyperopia, and astigmatism. This procedure, called LASIK, uses an excimer laser to reshape the cornea by precisely removing tissue via photoablation without causing thermal damage to the surrounding area.
Intraocular Lens (IOL) power calculation is a crucial step in cataract surgery and certain refractive surgeries like phakic IOL implantation. The goal is to determine the appropriate power of the IOL to be implanted into the eye, ensuring that the patient achieves their desired postoperative visual outcome. Several formulas and methods are available for IOL power calculation, and the choice of formula depends on various factors, including the patient's eye measurements and the surgeon's preference. Here, we describe the basic principles and some commonly used formulas.
Ocular Biometry:
Ocular biometry is the process of measuring various dimensions of the eye, primarily the axial length, corneal power, and anterior chamber depth. These measurements are essential for accurate IOL power calculation and achieving the desired post-surgical refractive outcome. Here are the key components of ocular biometry:
Axial Length: This measurement determines the overall length of the eye, from the cornea's front surface to the retina's back surface. Axial length is a critical factor in IOL power calculation because it helps determine the eye's focusing power.
Corneal Power: The cornea is the transparent front surface of the eye, and its curvature affects the eye's refractive power. Corneal power is typically measured using techniques like keratometry or corneal topography. It helps account for the eye's astigmatism and assists in selecting the appropriate IOL.
some basic notions on how they are measured is explored here.
The document discusses preoperative evaluation and measurements for cataract surgery, including biometry. It covers evaluating the general health and ocular history of the patient, performing visual acuity testing, refraction, and other objective tests. It then describes methods of measuring the eye, including A-scan biometry to determine axial length using ultrasound, and optical biometry using light waves. Factors that can influence biometry measurements and techniques like keratometry are also discussed. The document concludes by covering intraocular lens power calculation and selection, noting the importance of accurate measurements and various generation of formulas used.
Dry eye, also known as dysfunctional tear syndrome, is a multifactorial disease of the tears and ocular surface. It results in symptoms of discomfort, visual disturbance, and tear film instability, and can potentially damage the ocular surface. The document discusses the prevalence, classification, signs, symptoms, and diagnostic tests and tools for dry eye. The prevalence increases significantly with age and is higher in women. Diagnosis involves evaluating symptoms, performing a slit lamp exam to check for signs of damage, and conducting tests to assess tear film stability, tear secretion, and ocular surface damage. Management involves classifying dry eye severity levels based on signs and symptoms to determine appropriate treatment.
October 2017 laser and its applicationsVinitkumar MJ
Lasers have various applications in ophthalmology. The first working laser used in ophthalmology was created by Theodore Maiman in 1960 using a pulsed ruby laser. Lasers are used to treat glaucoma by creating iridotomies to relieve pupillary block. They are also used to treat diabetic retinopathy by destroying neovascular complexes and leaking blood vessels. Lasers are commonly used to perform posterior capsulotomies after cataract surgery. New techniques using YAG lasers aim to perform less traumatic cataract surgery through very small incisions.
This document discusses various diagnostic devices and therapeutic devices for dry eye disease. For diagnosis, it describes devices such as LipiView and LipiScan which measure lipid layer thickness and image meibomian glands, InflammaDry which detects inflammation biomarker MMP-9, TearLab and I-Pen which measure tear osmolarity, and Ocular Surface Analyser which performs multiple tear film tests. For treatment, it outlines thermal pulsation systems like LipiFlow, neurostimulation device TrueTear, intense pulse light therapy, BlephEx, iLux, and TearCare system which all aim to treat meibomian gland dysfunction and dry eye symptoms.
The document discusses various topics related to contact lenses and corneal treatments including:
1) Edge lift and edge clearance in contact lens design and their effects on tear exchange and lens movement.
2) Corneal topography, its uses in evaluating conditions like keratoconus and fitting contact lenses. Different topography devices are also mentioned.
3) Corneal cross-linking for progressive corneal conditions like keratoconus to strengthen the cornea using riboflavin and UV light. Various techniques and the procedure are outlined.
In this presentation slides I will discuss about Ocular tribology.
Ocular Tribology is concerned with the mechanisms of
contact lens lubrication.
There are three major driving forces in contact lens design
and development…
a. Cost
b. Convenience
c. Comfort
The document discusses strategies for improving rigid gas permeable (RGP) lens fitting practices. It notes declining RGP prescription rates and argues they remain a good option for many patients. It provides tips for practitioners, including improving RGP knowledge, using correct terminology with patients, starting difficult cases with RGPs, using anesthetic at fittings, ensuring proper edge shape and fit, charging appropriate fees, and not prejudging patients' ability to adapt to RGPs. The overall aim is to remind practitioners why RGPs are valuable and give ways to improve RGP prescription rates.
This document summarizes recent advancements in optometry. It discusses developments such as antimicrobial coatings for contact lenses, advancements in treating diabetic eye diseases using scatter laser treatment, stem cell therapy for retinal and optic nerve problems, Optiwave refractive analysis technology that allows surgeons to analyze eyes during cataract surgery, and Optos retinal scanning that eliminates the need for dilating drops and allows viewing of the entire retina. It also mentions visual prosthetics, advances in ocular drug delivery systems, and orthokeratology. Overall, the document outlines several important technological innovations that have improved eye care and vision correction.
This document proposes using spectrophotometry to non-invasively measure the water content of the human cornea in vivo. It is hypothesized that a slight change in corneal hydration can be measured using a spectrometer. The study aims to recruit 25 contact lens wearers and measure their central corneal thickness, intraocular pressure, and corneal water content before and after 2 hours of closed eye contact lens wear to investigate changes induced by lens-related edema. Quantifying corneal water content could help correct measurements of intraocular pressure and improve corneal surgery techniques by accounting for variations in corneal hydration and rigidity.
The document provides information about the anatomy and physiology of the eye. It discusses the various layers of the eye including the sclera, choroid, chambers and fluids, iris, lens, ciliary muscle, and retina. It also describes the functions of rods and cones and how light rays are focused in the eye. Common eye disorders like blepharitis, hordeolum, chalazion, entropion, ectropion, trichiasis, conjunctivitis, trachoma, keratitis, cataract, and glaucoma are defined and their causes, symptoms, diagnosis, and treatment are explained. Examination tools used in ophthalmology like the ophthalmoscope
Dry eye is a disease of the ocular surface caused by disturbances in the tear film. The normal tear film consists of an inner mucin layer, middle aqueous layer, and outer lipid layer, which work together to form a stable tear film. Disruptions to the tear film components or their functions can lead to dry eye. Common tests to diagnose dry eye include tear break-up time, fluorescein clearance, and tear osmolarity measurement, which help identify tear film instability and inflammation associated with the condition.
The document discusses the history and applications of lasers in orthodontics. It begins with the history of lasers, describing their development in the 1960s. It then covers the various types of lasers used in dentistry and orthodontics, including CO2, Nd:YAG, and diode lasers. Applications of lasers in orthodontics discussed include polymerizing adhesives, preventing enamel scars, increasing bracket bond strength, reducing pain, debonding brackets, facial analysis, digital models, gingival contouring, and measuring pulpal blood flow. Potential harmful effects like fires, eye damage, and laser plume are also reviewed. In conclusion, lasers are now an accepted treatment mod
Comparative Study of Visual Outcome between Femtosecond Lasik with Excimer La...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Similar to Anterior Segment Company Showcase - LacriScience (20)
This document provides an overview of a company called Aerie Pharmaceuticals and their glaucoma products. It summarizes clinical trial results for Rhopressa and Roclatan, which are novel glaucoma drugs. Rhopressa achieved non-inferiority compared to timolol in lowering eye pressure over 6 months in multiple trials. A pilot study found Rhopressa to be effective at lowering pressure during both day and night. Roclatan was statistically superior to its individual components latanoprost and Rhopressa in lowering pressure at all timepoints in a phase 3 trial. Both drugs were generally well tolerated with conjunctival hyperemia as the most common side effect.
This document provides an overview of a company called Aerie Pharmaceuticals and their glaucoma products. It summarizes results from clinical trials of their two leading investigational drug candidates, Rhopressa and Roclatan. Rhopressa achieved non-inferiority compared to timolol in lowering eye pressure over 6 months in phase 3 trials. A pilot study also found Rhopressa to be effective at lowering pressure during nighttime hours. Roclatan was found to be statistically superior to its individual components, latanoprost and Rhopressa, in lowering pressure at all timepoints in a phase 3 trial. Both drugs demonstrated favorable safety profiles in clinical testing.
This document discusses small aperture optics for improving vision, including the KAMRA corneal inlay and IC-8 intraocular lens. It summarizes clinical studies that show the KAMRA inlay and IC-8 IOL provide an extended depth of focus, improving intermediate and near vision while maintaining good distance vision. The document also notes that these technologies are capturing more market share and have the potential to address a significant segment of patients with aberrated corneas.
This document provides an overview of Avedro, the world leader in corneal remodeling. Key points include:
- Avedro has developed the first and only FDA-approved corneal cross-linking platform for treating keratoconus and corneal ectasia. They have installed 1500 systems and performed 250,000 treatments.
- Their 2017 plans are to expand into keratoconus and refractive markets, drive toward reimbursement, and conduct 14 clinical studies on epi-on procedures and refractive applications.
- They have a proven cross-linking mechanism of action that strengthens the cornea to stabilize keratoconus and ectasia. Their PiXL technique allows for non-invasive zonal strengthening to induce corneal
The HARMONI Modular IOL System provides a stable foundation through a reliable base and optimized rotational stability. Its modular design allows for versatile control through safe and easy optic exchangeability and upgradeability to provide refractive care for a patient's lifetime. Clinical trials show the HARMONI IOL has best-in-class stability and visual performance that rivals traditional IOLs, while offering the ability to fine tune outcomes through optic exchange. The system aims to provide complete confidence in surgical outcomes without added costs or changes to routines.
EyeGate Pharmaceuticals is developing two drug delivery platforms - a crosslinked hyaluronic acid eye drop called Ocular Bandage Gel to promote wound healing after corneal surgery or injuries, and an iontophoresis delivery system to administer the corticosteroid dexamethasone phosphate (EGP-437) after cataract surgery or for anterior uveitis. Positive pilot clinical trial data was announced for Ocular Bandage Gel in accelerating wound healing after photorefractive keratectomy. Later stage clinical trials are underway or planned for EGP-437 to reduce inflammation for cataract surgery and uveitis, with FDA filings targeted for 2018. EyeGate licensed worldwide commercial rights for EGP-
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)Healthegy
The InnFocus MicroShunt is designed to be the first FDA-approved standalone procedure to treat mild, moderate, and severe open-angle glaucoma by lowering intraocular pressure under 15 mmHg without eye drops in most patients. It uses a unique SIBS material that has been proven biocompatible and shown not to degrade or provoke scarring over 15 years of use in over 1 million patients. Clinical trials have demonstrated the MicroShunt's ability to successfully lower IOP long-term while maintaining an acceptable safety profile. The MicroShunt offers surgeons a potential replacement for trabeculectomy and tubes with advantages in both safety and operating time.
The document discusses the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device that provides a tri-modal mechanism of action to lower intraocular pressure. Over 3,200 patients have been treated globally using the Hydrus Microstent. Clinical studies and a large global registry have shown the Hydrus Microstent to provide superior outcomes compared to other MIGS devices, with a 20% reduction in diurnal intraocular pressure and increased treatment response rates. The Hydrus Microstent expands treatment opportunities for both standalone glaucoma procedures and combined cataract/glaucoma surgeries.
Ophthalmology Innovation Showcase 1 - Mati TherapeuticsHealthegy
This document discusses a punctal plug drug delivery system called Evolute. It can deliver drugs to treat various ocular diseases like glaucoma, allergies, inflammation, and dry eye. Clinical trials showed excellent plug retention rates over 12 weeks. The system offers benefits like a flexible drug delivery profile, non-invasive application, steady drug elution unlike eye drops, and comfort. It is developing formulations of nepafenac, difluprednate, travoprost, olopatadine, and cyclosporine to treat conditions like post-cataract pain/inflammation and glaucoma. The company has a strong intellectual property position and plans upcoming clinical trials.
Ocular Therapeutix is developing sustained-release drug therapies for ophthalmic conditions to improve patient outcomes and compliance. Their lead product, DEXTENZA, is an intracanalicular insert delivering dexamethasone for up to 30 days after cataract surgery to reduce pain and inflammation. Phase 3 trials showed DEXTENZA was well-tolerated and effective in meeting primary efficacy endpoints. If approved, DEXTENZA could become the new standard of care by replacing complex topical drop regimens. The company is also developing sustained-release therapies for glaucoma and posterior segment diseases in collaboration with Regeneron.
The document expresses gratitude but does not provide any further details. It is a very short document consisting of only two words with no other context provided.
Presbyopia Therapies is developing LiquidVision Eye Drops to treat presbyopia, a large global market affecting most people over age 50. The drops aim to improve near vision without distance vision blur for 5+ hours after a single daily dose. Currently, the main treatment options are reading glasses or contact lenses. A phase 2a trial in 2016 showed the drops improved uncorrected near vision versus placebo. A phase 2b trial beginning in Q2 2017 aims to demonstrate a 30 minute onset and 5+ hour duration with a 3-line improvement in near vision. The company hopes to create a new global market category for the daily treatment of presbyopia.
The document discusses market research data on the presbyopic market in the US and patient outcomes and satisfaction rates for Raindrop vision correction surgery. It finds that there are over 28 million potential patients in the US, with 71% seeking an ophthalmologist for the procedure. Real-world data shows 99% of patients achieving less than 20/20 distance vision and 78% less than J3 near vision, with a low 2.5% explant rate. Surgeon, patient, and reorder satisfaction rates are over 90% based on recent surveys.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The Commonwealth Fund - Putting the Patient at the Center of the Digital Univ...Healthegy
Keynote Address - Presentation by Commonwealth Fund at Digital Healthcare Innovation Summit 2016
Participant:
David Blumenthal, MD, MPP, President & CEO – Commonwealth Fund
Introduced By:
Robert Mittendorff, MD, MBA, Partner – Norwest Venture Partners
Powered by:
Healthegy
For more healthcare innovation
Visit us at Healthegy.com
StartUp Health - Private Market Perspectives - Digital Healthcare Innovation ...Healthegy
Startup Health Insights provides an in-depth analysis of digital health funding and trends. It is promoting Startup Health's mission to transform global health and wellbeing through 10 "moonshot" goals within their 25-year vision. The document summarizes digital health funding trends in 2016, showing continued growth in funding rounds and deals particularly in patient/consumer experience technologies. It provides an overview of the most active subsectors and largest deals of the year to date.
Masters of the Industry at OIS@AAO 2016.
Moderated By:
Jim Mazzo, Global President Ophthalmic Devices - Carl Zeiss Meditec
Participants:
Flemming Ornskov, MD, CEO - Shire
Mike Ball, CEO - Alcon
Ashley McEvoy, Company Group Chairman - Johnson & Johnson Vision Care
William J. Link, PhD, Managing Director - Versant Ventures
Ludwin Monz, PhD, President & CEO - Carl Zeiss Meditec
William Meury, Chief Commercial Officer - Allergan
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Anterior Segment Company Showcase - EnvisiaHealthegy
Anterior Segment Company Showcase - Envisia at OIS@AAO 2016.
Presenter:
Benjamin Yerxa, PhD, President
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Mercurius is named after the roman god mercurius, the god of trade and science. The planet mercurius is named after the same god. Mercurius is sometimes called hydrargyrum, means ‘watery silver’. Its shine and colour are very similar to silver, but mercury is a fluid at room temperatures. The name quick silver is a translation of hydrargyrum, where the word quick describes its tendency to scatter away in all directions.
The droplets have a tendency to conglomerate to one big mass, but on being shaken they fall apart into countless little droplets again. It is used to ignite explosives, like mercury fulminate, the explosive character is one of its general themes.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Anterior Segment Company Showcase - LacriScience
1. The LacriPen™ – A Handheld
Portable Ophthalmic Osmometer
and Diagnostic Instrument
…a portable laboratory in the palm of your hand
Presented by:
Dr Chris D. Geddes, Ph.D., FRSC
Professor, University of Maryland (UMBC)
for
LacriScience LLC, Paul T. Gavaris MD
Managing Member